Drug Resistant Epilepsy Articles & Analysis
13 news found
The jointly developed therapy features a micro-infusion device that tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. ...
“About a third of individuals with epilepsy have drug-resistant seizures. Removal or ablation of the affected temporal lobe can be an option, but many people with epilepsy are not eligible or interested in a tissue-destructive procedure. ...
Neurona’s lead product candidate, NRTX-1001, a targeted inhibitory neuron cell therapy derived from human pluripotent stem cells, is designed to repair hyperexcitable neural networks that underlie epilepsy, as well as other disorders of the nervous system, and is being evaluated for safety and efficacy in a Phase 1/2 multicenter clinical trial in people with ...
NRTX-1001 is being evaluated in a Phase 1/2 clinical trial in people with drug-resistant mesial temporal lobe epilepsy. The data are being presented at the annual meeting of the American Academy of Neurology (AAN) held April 2-7, 2022 in Seattle, WA. ...
” The FDA’s Breakthrough Device Program is designed to give patients more timely access to novel technologies, like the Monarch eTNS System, that provide more effective treatments for life-threatening or irreversibly debilitating human diseases and conditions. Drug-resistant epilepsy (DRE) occurs in approximately 30% of ...
NeuroSigma is the developer of the Monarch eTNS System®, which uses non-invasive, external trigeminal nerve stimulation (eTNS) to treat neurological and neuropsychiatric indications, including ADHD, depression, and drug resistant epilepsy. The therapy is the first device-based, non-drug therapy approved by the FDA to treat ...
Neurona’s lead product candidate; NRTX1001, a targeted neural cell therapy derived from human pluripotent stem cells, is designed to repair hyperexcitable neural networks that underlie epilepsy, as well as other disorders of the nervous system, and is being evaluated in a first in human Phase 1/2 multicenter clinical trial in people with ...
Blum, a neurologist by training, is also a seasoned pharmaceutical executive who has secured drug approvals in the U.S., Canada and Europe and designed the first-in human clinical trial of NRTX-1001 for chronic focal ...
“These preclinical data, in a model of drug-resistant epilepsy, demonstrate that a single administration of NRTX-1001 achieves durable and significant suppression of seizures and reduction of hippocampal pathology, important metrics for the potential resolution of chronic focal-onset epilepsy. ...
(Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Neurona Therapeutics on clearance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application to initiate its first-in-human Phase 1/2 clinical trial evaluating the ...
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation (TNS) technology to treat neurological and neuropsychiatric disorders, announced today that the following patents have issued or received notices of allowance in Canada and Japan: Canadian patent no. 2776694 entitled Devices, Systems, and Methods for Treatment of Neuropsychiatric ...
"NeuroSigma's Monarch eTNS System was the first non-drug treatment for pediatric ADHD cleared by the FDA. Starting April 1st of this year, payers will be able to use these unique new HCPCS codes to establish coverage policies and payment decisions," said Ian Cook, M.D., Chief Medical Officer of NeuroSigma. ...
CanaQuest has identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions. ...